Cyclacel Pharmaceuticals Inc Pref Share CYCCP
Find similar stocks with Morningstar Investor.
Morningstar analysts do not currently cover CYCCP, but with our powerful screener, you can find stocks in the same sector, industry, or style and filter on our unbiased ratings and valuation metrics.
News
-
Cyclacel Pharmaceuticals to Present New Clinical Data at 2024 ASCO Annual Meeting Highlighting Fadraciclib’s Potential as a Precision Medicine for Cancer
-
Cyclacel Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
-
Cyclacel Pharmaceuticals to Release Fourth Quarter and Full Year 2023 Financial Results
-
Cyclacel Pharmaceuticals Announces Preclinical Proof-of-Concept Data for Fadraciclib to be Presented at the American Association for Cancer Research (AACR) Annual Meeting 2024
-
Cyclacel Pharmaceuticals Announces Receipt of $2.9 Million R&D Tax Credit
-
Cyclacel Pharmaceuticals to Participate in 2024 BIO CEO & Investor Conference
-
Cyclacel Pharmaceuticals Announces the Appointment of Brian Schwartz, M.D. as Chief Medical Officer
Trading Information
- Previous Close Price
- $11.50
- Day Range
- $12.50–13.50
- 52-Week Range
- $5.25–22.20
- Bid/Ask
- $12.14 / $14.86
- Market Cap
- $4.53 Mil
- Volume/Avg
- 1,836 / 1,152
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- —
- Dividend Yield (Trailing)
- 3.40%
- Dividend Yield (Forward)
- 3.40%
- Total Yield
- 3.40%
Company Profile
Cyclacel Pharmaceuticals Inc is a clinical-stage biopharmaceutical company that develops targeted medicines for cancer and other proliferative diseases. The company develops several families of anticancer drugs that act on the cell cycle, including CDK (cyclin-dependent kinase) inhibitors, and PLK (polo-like kinase) inhibitors. The pipeline development programs of the company include fadraciclib, Sapacitabine, and plogosertib.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Value
- Total Number of Employees
- 12
- Website
- https://cyclacel.com
Valuation
|
Metric
|
CYCCP
|
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | — |
Price/Sales | — |
Price/Cash Flow | — |
Price/Earnings
No chart available
Financial Strength
|
Metric
|
CYCCP
|
|---|---|
Quick Ratio | 0.87 |
Current Ratio | 0.91 |
Interest Coverage | — |
Quick Ratio
CYCCP
Profitability
|
Metric
|
CYCCP
|
|---|---|
Return on Assets (Normalized) | −120.97% |
Return on Equity (Normalized) | −214.22% |
Return on Invested Capital (Normalized) | −215.11% |
Return on Assets
CYCCP
Biotechnology Industry Comparables
|
Ticker
|
Name
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|
NVO
| Novo Nordisk A/S ADR | Wdtxcplbj | Hyw | $557.8 Bil | |
VRTX
| Vertex Pharmaceuticals Inc | Ttkztykm | Rxdcs | $103.3 Bil | |
REGN
| Regeneron Pharmaceuticals Inc | Tzkdwxq | Cpmfbd | $98.8 Bil | |
MRNA
| Moderna Inc | Xxtgxslr | Twpms | $38.8 Bil | |
ARGX
| argenx SE ADR | Nfrpxnskr | Zrgz | $21.3 Bil | |
BNTX
| BioNTech SE ADR | Qxtdmnz | Nvhn | $20.8 Bil | |
ALNY
| Alnylam Pharmaceuticals Inc | Jtqyxdvs | Pfbwsd | $18.4 Bil | |
BMRN
| Biomarin Pharmaceutical Inc | Wwydytp | Gzbdbb | $17.0 Bil | |
RPRX
| Royalty Pharma PLC Class A | Kmtzsrysvs | Hjqfvq | $12.4 Bil | |
INCY
| Incyte Corp | Vbrtjzjq | Ndryjc | $11.9 Bil |